The Lancet Oncology

The Lancet Oncology is a monthly peer-reviewed clinical oncology journal published by Elsevier, founded in 2000 as an early specialty title in the Lancet group, covering all aspects of clinical cancer care, with a 2025 Journal Impact Factor of 33.7《柳叶刀：肿瘤学》是（Elsevier）出版的月刊同行评审临床肿瘤学期刊，2000 年创刊，为（The Lancet）集团早期的专科刊物，涵盖临床肿瘤诊疗的各个方面，2025 年影响因子为 33.7。

Scope

• It is the world-leading clinical oncology journal, publishing high-quality peer-reviewed original research, especially reports from clinical trials该刊是世界领先的临床肿瘤学期刊，刊载高品质的同行评审原创研究，尤其是临床试验报告。^[1]
• It also publishes reviews, comment and opinion, weekly news, and Commissions, typically in partnership with societies, governments, NGOs and academy centres该刊还刊载综述、评论与观点、每周新闻以及（Commissions）专题报告，后者通常与学会、政府、非政府组织及学术中心合作。
• Its content covers international issues relevant to clinical cancer specialties worldwide其内容涵盖与全球各临床肿瘤专科相关的国际议题。
• Its articles advance clinical practice, challenge the status quo, advocate change in health policy and tackle issues related to global oncology其文章推动临床实践、挑战现状、倡导卫生政策变革，并应对全球肿瘤学相关问题。
• Its aim is to publish interesting and informative research on any topic connected with oncology其宗旨是发表与肿瘤学相关的任何主题的、有趣且具信息量的研究。
• It provides definitive coverage of all aspects of oncology from around the world in a single readable source该刊以单一而可读的形式，提供全球肿瘤学各个方面的权威报道。

History

• It was established in 2000 as one of the first specialty journals spun off from The Lancet, and its first issue appeared in 2000该刊于 2000 年创刊，是（The Lancet）最早分设的专科刊之一，首期于 2000 年出版。
• Richard Horton, Editor-in-Chief of The Lancet since 1995, launched three offspring in quick succession, and The Lancet Oncology was one of them自 1995 年起任（The Lancet）主编的 Richard Horton 相继创办了三本子刊，（The Lancet Oncology）即为其一。
• David Collingridge has served as Editor-in-Chief of the journal since March 2002David Collingridge 自 2002 年 3 月起担任该刊主编。
• It is published by Elsevier and forms part of the Lancet Group's portfolio of specialty journals该刊由（Elsevier）出版，隶属（The Lancet）集团的专科期刊组合。
• It extended into the field of primary research from May 2005该刊自 2005 年 5 月起拓展到原创研究领域。
• Its 2025 Journal Impact Factor is 33.7, ranking ninth among 333 oncology journals其 2025 年影响因子为 33.7，在 333 种肿瘤学期刊中排名第九。

Editors

• The Editor-in-Chief is David Collingridge, PhD, who has held the post since March 2002现任主编为 David Collingridge，拥有博士学位，自 2002 年 3 月起担任该职。
• He is also Vice President of editorial strategy and innovation for The Lancet's portfolio of clinical journals他同时担任（The Lancet）系列临床期刊的编辑战略与创新副总裁。
• He gained a PhD in Tumour Biology from the Gray Cancer Institute at University College London他在（University College London）的（Gray Cancer Institute）取得肿瘤生物学博士学位。
• Before joining The Lancet he held research posts at Yale University and the Hammersmith Hospital PET Oncology unit加入（The Lancet）之前，他曾在（Yale University）与（Hammersmith Hospital）的 PET 肿瘤学研究部门任职。
• He is a Visiting Professor of Global Oncology at King's College London他是（King's College London）的全球肿瘤学访问教授。
• As part of the Lancet Group, the journal shares editorial standards with the group's other specialty journals作为（The Lancet）集团的一员，该刊与集团其他专科刊共享编辑标准。